Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

Table 1 Unit costs (EUR 2019)

Type	Sweden		Norway
Type	Cost (EUR)	Source	Cost (EUR)	Source
*Treatments*
Botox (PSP)	347	[29]	335	[30]
Placebo	–	–	–	–
*Administration*
Neurology consultant appointment	279	[31]	248	[32]
Specialist nurse appointment	86	[33]	50	[34]
*Resources*
GP appointment	155	[31]	33	[35]
A&E visit	279	[31]	73	[35]
Hospitalisation (per day)	665	[31]	771	[32]
Cost of triptans (per attack)	2	[29]	4	[36]
*Productivity*
Average hourly wage	40	[37, 38]	45	[34]
*Additional inputs used in COI analyses*
Value of spare time/hour	11	[39]	–	–
Value of spare time, retail price/hour	22	[40, 41]	–	–
GP appointment (acute)	369	[31]	–	–

Key: A&E Accident and emergency; GP General practitioner; PSP Pharmacy selling price; VAT Value added tax
Note: In Norway the VAT for pharmaceuticals is 25%, while there is no VAT for prescription pharmaceuticals in Sweden. The analyses were undertaken excluding VAT. All Swedish unit costs except average wage are sourced from 2019. Average wage was inflated from 2018 to 2019 values using CPI from Statistics Sweden [42]. Some of the Norwegian unit costs have been inflated to 2019 values using CPI from Statistics Norway [43]. All costs are presented in EUR, using ECB average annual 2019 NOK/EUR and SEK/EUR exchange rates [44, 45]

ISSN: 1129-2377